PL2616101T3 - Sposób oczyszczania pegylowanej erytropoetyny - Google Patents

Sposób oczyszczania pegylowanej erytropoetyny

Info

Publication number
PL2616101T3
PL2616101T3 PL11754693T PL11754693T PL2616101T3 PL 2616101 T3 PL2616101 T3 PL 2616101T3 PL 11754693 T PL11754693 T PL 11754693T PL 11754693 T PL11754693 T PL 11754693T PL 2616101 T3 PL2616101 T3 PL 2616101T3
Authority
PL
Poland
Prior art keywords
pegylated erythropoietin
purifying pegylated
purifying
erythropoietin
pegylated
Prior art date
Application number
PL11754693T
Other languages
English (en)
Inventor
Roberto Falkenstein
Wolfgang Koehnlein
Wolfgang Kuhne
Hartmut Schurig
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2616101T3 publication Critical patent/PL2616101T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11754693T 2010-09-14 2011-09-13 Sposób oczyszczania pegylowanej erytropoetyny PL2616101T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10176616 2010-09-14
PCT/EP2011/065888 WO2012035037A1 (en) 2010-09-14 2011-09-13 Method for purifying pegylated erythropoietin
EP11754693.7A EP2616101B1 (en) 2010-09-14 2011-09-13 Method for purifying pegylated erythropoietin

Publications (1)

Publication Number Publication Date
PL2616101T3 true PL2616101T3 (pl) 2015-01-30

Family

ID=43385653

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11754693T PL2616101T3 (pl) 2010-09-14 2011-09-13 Sposób oczyszczania pegylowanej erytropoetyny

Country Status (14)

Country Link
US (4) US20120197007A1 (pl)
EP (1) EP2616101B1 (pl)
JP (1) JP5735650B2 (pl)
KR (1) KR101578586B1 (pl)
CN (1) CN103118708B (pl)
BR (1) BR112013005890B1 (pl)
CA (1) CA2808748C (pl)
DK (1) DK2616101T3 (pl)
ES (1) ES2500048T3 (pl)
MX (1) MX342444B (pl)
PL (1) PL2616101T3 (pl)
RU (1) RU2566267C2 (pl)
SI (1) SI2616101T1 (pl)
WO (1) WO2012035037A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
DE102016210647B3 (de) 2016-06-15 2017-09-14 Schaeffler Technologies AG & Co. KG Keilkupplung-Synchronisation
WO2018011381A1 (en) * 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
PL3731873T3 (pl) * 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
CN111801120A (zh) 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
SG88714A1 (en) 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
DE779362T1 (de) 1989-12-22 2001-04-05 Applied Research Systems Ars Holding N.V., Curacao DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
DE4118912C1 (pl) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO2000044785A1 (en) 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
PT1543038T (pt) * 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2005021710A2 (en) 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
SE0401951D0 (sv) 2004-07-29 2004-07-29 Amersham Biosciences Ab Chromatography method
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CA2736141C (en) 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药

Also Published As

Publication number Publication date
RU2566267C2 (ru) 2015-10-20
US20120197007A1 (en) 2012-08-02
BR112013005890B1 (pt) 2022-02-08
KR20130073964A (ko) 2013-07-03
SI2616101T1 (sl) 2014-10-30
MX2013002554A (es) 2013-05-28
HK1181661A1 (en) 2013-11-15
WO2012035037A1 (en) 2012-03-22
DK2616101T3 (da) 2014-08-04
MX342444B (es) 2016-09-29
KR101578586B1 (ko) 2015-12-17
ES2500048T3 (es) 2014-09-29
JP2013537208A (ja) 2013-09-30
CN103118708B (zh) 2015-08-26
CN103118708A (zh) 2013-05-22
RU2013113724A (ru) 2014-10-20
US20170008941A1 (en) 2017-01-12
US20140163207A1 (en) 2014-06-12
EP2616101A1 (en) 2013-07-24
US10273277B2 (en) 2019-04-30
US20210094993A1 (en) 2021-04-01
JP5735650B2 (ja) 2015-06-17
EP2616101B1 (en) 2014-07-09
CA2808748A1 (en) 2012-03-22
BR112013005890A2 (pt) 2020-04-14
CA2808748C (en) 2018-09-11

Similar Documents

Publication Publication Date Title
SI2608541T1 (sl) Postopek za dekodiranje notranjih napovedi
GB201001833D0 (en) Method
EP2613857A4 (en) PROCESS FOR PURIFYING IMMUNOCONJUGATES OR ACTIVE POLYPEPTIDES
GB201716070D0 (en) Catalysts
HUE045412T2 (hu) Katalizátor elõállítási eljárás
GB201012599D0 (en) Process for purifying proteins
GB201007353D0 (en) Method
GB201004759D0 (en) Method
GB201011513D0 (en) Method
GB201007354D0 (en) Method
HU1000330D0 (en) Novel method
SI2616101T1 (sl) Postopek za čiščenje pegiliranega eritropoetina
GB201006306D0 (en) Method
ZA201302330B (en) Method for purifying water
EP2743259A4 (en) PROCESS FOR CLEANING (S) -OXIRACETAM
GB201012148D0 (en) Method
EP2743258A4 (en) PROCESS FOR PURIFYING LEVO-OXIRACETAM
IL209654A0 (en) Method for purifying erythropoietin
GB201012784D0 (en) Method
GB201010855D0 (en) Method
GB201007207D0 (en) Method
GB201017003D0 (en) Method
GB201007522D0 (en) Method
GB201010852D0 (en) Method
GB201021028D0 (en) Method